Market Intelligence, Clinical Progress, and High-Purity Reagents for Precision Oncology Development.
Target Overview
MAP2K2 (also known as MEK2) is a dual-specificity protein kinase belonging to the MAP kinase kinase family. It is a key node in the RAS-RAF-MEK-ERK signaling cascade. The functional domain includes a Protein kinase domain (UniProt P36507). Clinically relevant mutations associated with CFC4 syndrome include rs121434497, rs121434498, and rs267607230, which result in increased kinase activity.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for MAP2K2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MAP2K2 WT & Mutant Proteins (including CFC4-associated variants). High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. | View MAP2K2 Products |
| Gene Delivery | MAP2K2 Promise-ORF / Lentivirus. Full-length ORF for stable Ba/F3 or HEK293 cell lines. | View MAP2K2 Products |
| Detection Ab | Anti-MAP2K2 Recombinant Rabbit mAb. For target engagement validation (WB/IP/IF). Sequence Verified. | View MAP2K2 Products |
| Validator | MAP2K2 siRNA Set. For knockdown verification and specificity controls. | View MAP2K2 Products |
| Related Target – MEK1 | MAP2K1/MEK1. Homolog protein for selectivity counter-screening; 85% kinase domain homology. | View MAP2K1 Products |
| Related Target – ERK2 | MAPK1/ERK2. Downstream substrate for pathway reconstitution and bypass resistance studies. | View MAPK1 Products |
| Related Target – KRAS | KRAS (WT, G12C, G12D, G12V). Upstream oncogenic driver; combination therapy context. | View KRAS Products |
| Related Target – BRAF | BRAF. Upstream kinase; synergistic combination target for overcoming resistance in melanoma/NSCLC. | View BRAF Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Resistance Mutation Profiling (CFC4 mutants) | MAP2K2 Mutant Panel: Sequence-verified resistance variants; Purity >95%, Endotoxin <1 EU/µg |
| Isoform Selectivity (MEK1 vs MEK2) | Purified Human MAP2K1 and MAP2K2 proteins available for side-by-side screening |
| Target Engagement & Specificity | Anti-MAP2K2 Recombinant mAb + MAP2K2 siRNA Set for orthogonal validation |
| Lack of Cellular Controls | MAP2K2 Lentivirus for stable cell line construction |
| Cellular Pathway Validation | Validated lentivirus to build stable MAP2K2 over-expressing cell lines for phenotypic assays |
Live MAP2K2/MEK2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for MAP2K2/MEK2 therapeutics has intensified, driven by the profound dependence of various tumors on the RAS-RAF-MEK-ERK signaling pathway. Historically, successful clinical interventions have relied on allosteric pan-MEK inhibitors (targeting both MEK1 and MEK2). However, as first-generation therapies face clinical limitations due to acquired resistance and toxicity (such as dermatologic and gastrointestinal adverse events), the next wave of R&D is shifting. Emerging trends highlight the development of MEK PROTACs (protein degraders), highly selective mutant-sparing inhibitors, and synergistic combination regimens pairing MEK inhibitors with KRAS or BRAF blockers.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Allosteric) | Novartis, Roche, Pfizer | Melanoma, NSCLC, CRC | High-throughput Screening Assays (Need high-purity Kinase proteins) |
| Combination Therapy (MEK + KRAS/ERK) | Array BioPharma (Pfizer), Roche, AstraZeneca | Pancreatic, Colorectal, KRAS-mutant Cancers | Pathway Reconstitution (Need MAPK1/ERK2 + KRAS Mutant Proteins) |
| Next-Gen Mutant-Selective MEK | Various Biotechs | Refractory Solid Tumors | Resistance Panel Screening (Need CFC4 Mutants) |
| Targeted Protein Degrader (PROTAC) | Emerging Biotech | Refractory Solid Tumors | Ternary Complex Validation (Need purified WT and Mutant proteins) |